Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
Anaplastic lymphoma kinase (ALK) gene rearrangements are found in approximately 5% of non-small cell lung carcinoma patients and confer sensitivity to ALK inhibitors such as crizotinib. The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic.
Massachusetts General Hospital Cancer Center; and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
Adam S
AS
Crystal
Alice T
AT
Shaw
D000077548:Anaplastic Lymphoma Kinase; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation; D000077547:Crizotinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D055550:Protein Stability; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism
D054316:Biomarkers, Pharmacological; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases